- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04644003
Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder
February 1, 2022 updated by: Stalicla SA
A Phase 1b, Double-Blind, Placebo-Controlled, First-in-Human Study to Evaluate Safety, Tolerability and Pharmacokinetics of a Two-Week Oral Treatment With STP1 in a Subgroup of Patients With Autism Spectrum Disorder
The main purpose of this study is to evaluate safety and tolerability, Pharmacokinetics and Pharmacodynamics, as well as exploratory efficacy of STP1, in a subgroup of patients with Autism Spectrum Disorder (ASD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
After obtaining written informed consent, those patients who are deemed eligible for the study, will be randomized on Day 1, in a double-blinded manner, in a 3:1ratio to receive either oral STP1 (twice daily) or placebo (twice daily).
The total study duration is 6 weeks, including a screening phase of up to 2 weeks, a treatment phase of 2 weeks and a post-treatment follow-up phase of 2 weeks.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 38 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Male or female individuals, between 18 and 40 years, diagnosed of ASD.
- Patients will be assessed for specific developmental anthropometric & anatomical criteria as well as personal and family medical history as assessed by the ASD-Phen1 semi structured interview form.
- Patients must have a parent or reliable caregiver who can provide information about the pre-natal period and early developmental period, as required by the protocol.
- Patient and/or parent or legal guardian willing and consenting to participate.
- Patients with ASD and comorbid seizure disorder should be seizure-free for at least 6 months prior to screening.
- Before enrolling in the study, subjects must agree to use double-barrier birth control methods if they engage in intercourse.
Key Exclusion Criteria:
- Patients with an identified genetic cause of ASD in their medical record will be excluded from the study.
- History of traumatic head injury, cerebrovascular disorder, congestive heart failure, hepatic or renal disease.
- Thrombocytopenia.
- Type 1 Diabetes Mellitus or uncontrolled type 2 Diabetes Mellitus, or latent autoimmune diabetes of the adult.
- A significant risk for suicidal behavior.
- Initiation of, or a major change in psychological / behavioral intervention within 4 weeks prior to randomization.
- Patient with any active infection.
- Systolic blood pressure (SBP) <80 mmHg or diastolic blood pressure (DBP) <40 mmHg or a drop in SBP of ≥20 mm Hg, or in DBP of ≥10 mm Hg, during the orthostatic recordings.
- Clinically relevant electrocardiogram (ECG) abnormalities.
- Clinically significant abnormal laboratory test.
- Active clinically significant disease.
- History of malignancy.
- Pregnant (confirmed by laboratory testing) or lactating female patient.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: STP1 Low Dose
1 capsule and 1 tablet per intake
|
STP1 is a combination of two drugs, a PDE inhibitor and an NKCC1 inhibitor
|
Experimental: STP1 High Dose
1 capsule and 1 tablet per intake
|
STP1 is a combination of two drugs, a PDE inhibitor and an NKCC1 inhibitor
|
Placebo Comparator: Placebo
1 placebo capsule and 1 placebo tablet per intake
|
Placebo medication (capsule and tablet) identical in appearance to active medication
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability
Time Frame: 28 days
|
Incidence, nature and severity of adverse events, serious adverse events and adverse events of special interest
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma concentration of STP1 (PK)
Time Frame: Day 1, Day 7, Day 14, Day 15 (and optionally: Day 16, Day 17 and Day 18)
|
Standard non-compartmental analysis
|
Day 1, Day 7, Day 14, Day 15 (and optionally: Day 16, Day 17 and Day 18)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ABC-C: Aberrant Behavior Checklist-Community
Time Frame: 28 days
|
Assess maladaptive behaviors across 5 original subscales: Irritability, Social Withdrawal, Stereotypic Behavior, Hyperactive/non-compliance, Inappropriate Speech
|
28 days
|
OACIS: Ohio Autism Clinical Impression Scale
Time Frame: 28 days
|
The OACIS is composed of two scales: the OACIS-Severity scale (OACIS-S), which measures global severity of illness at a given point in time as well as scores for 9 anchors: social interactions; aberrant/abnormal behaviors; repetitive/ritualistic behaviors; verbal communication; non-verbal communication; hyperactivity/inattention; anxiety/fears; sensory sensitivities; restricted and narrow interests and the OACIS improvement scale (OACIS-C), which permits a global evaluation by the clinician of the subject's improvement over time.
The OACIS-S is a 7-point scale ranging from 1 (no symptoms) to 7 (very severe).
The OACIS-C is a seven-point scale, ranging from 1 (very much improved) to 7 (very much worse).
|
28 days
|
CGI-S: Clinical Global Impressions-Severity reflected by the Clinical Global Impressions-Improvement (CGI-I) scale
Time Frame: 28 days
|
Illness severity rating is made on a scale of 1 to 7, with 1 being "normal not at all mentally ill" and 7 being "among the most extremely ill patients".
Subsequently, the patient's condition on the study drug (or placebo) is compared to the patient's condition before the initiation of the study drug (or placebo) (baseline) via additional CGI-S ratings or the CGI-I item.
The CGI is a clinician-rated scale utilizing history from the caregiver and incorporating it into a clinical rating.
The CGI-I will be used to judge the change in clinical impression as 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment
|
28 days
|
NIH-TCB: NIH Toolbox Cognitive Battery
Time Frame: 28 days
|
Computer-based test, that assesses cognition
|
28 days
|
KiTAP test battery: The Test of Attentional Performance
Time Frame: 28 days
|
The KiTAP test is a computer-based Continuous Performance Tasks (CPT) and Executive Function (EF) battery test
|
28 days
|
Social Responsiveness Scale, 2nd Edition (SRS-2)
Time Frame: 28 days
|
The SRS-2 is a 65-item parent/caregiver rating scale used to assess the severity of social impairment within patients with ASD.
|
28 days
|
CSHQ: Children Sleep Habit Questionnaire
Time Frame: 28 days
|
The CSHQ is a retrospective, 45-item parent questionnaire, which includes items relating to a number of key sleep domains that encompass the major presenting clinical sleep complaints in this age group: bedtime behavior and sleep onset; sleep duration; anxiety around sleep; behavior occurring during sleep and night wakings; sleep-disordered breathing; parasomnias; and morning waking/daytime sleepiness.
|
28 days
|
EEG: Electroencephalogram
Time Frame: 28 days
|
Auditory Event Related Potentials (ERP) will be measured.
|
28 days
|
Eye-tracking
Time Frame: 28 days
|
Change from baseline in eye gaze to eye regions during viewing of static faces and change in eye gaze to social scene viewing during viewing of dynamic video
|
28 days
|
Lactate/Pyruvate Ratio - L:P
Time Frame: 28 days
|
Change from baseline, measured in blood
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 7, 2020
Primary Completion (Actual)
January 28, 2022
Study Completion (Actual)
January 28, 2022
Study Registration Dates
First Submitted
November 16, 2020
First Submitted That Met QC Criteria
November 24, 2020
First Posted (Actual)
November 25, 2020
Study Record Updates
Last Update Posted (Actual)
February 17, 2022
Last Update Submitted That Met QC Criteria
February 1, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STP1-C004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hoffmann-La RocheActive, not recruitingAutism Spectrum Disorder (ASD)United States, Canada, Italy, Spain
-
Axial Therapeutics, Inc.Active, not recruitingAutism Spectrum Disorder (ASD)United States, Australia, New Zealand
-
Technion, Israel Institute of TechnologyCompleted
-
Stanford UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAutism | Autism Spectrum Disorder (ASD)United States
-
Corporacion Parc TauliUnknown
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyTerminatedAutism Spectrum Disorder (ASD)Spain, United States, Hungary, Poland, Australia, United Kingdom, Brazil, Czechia, France, Italy, Portugal, Slovakia
-
Florida Gulf Coast UniversityCompletedAutism Spectrum Disorder High-FunctioningUnited States
-
Hospital Universitario Dr. Jose E. GonzalezUnknownAutism | Autism SpectrumMexico
-
National Taiwan University HospitalCompletedAutism Spectrum Disorder High-FunctioningTaiwan